All lobbying filings

THE CONSILIO GROUP

THE CONSILIO GROUP filed a Q4 report for N BRERETON MEDICAL TECHNOLOGIES on April 9, 2026, reporting $15,000 in lobbying income.

Lobbying for N BRERETON MEDICAL TECHNOLOGIES · Opiod prevention through a titration-based methodology.

All filings by THE CONSILIO GROUP · Everything N BRERETON MEDICAL TECHNOLOGIES has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Apr 9, 2026

Income

$15,000

What the client paid this registrant for the period.

Client based in

Virginia

Official filing document

Lobbyists on this filing 2

OLIVER MEISSNER

Previously held: CEO
BRANDON KIRBY

Previously held: Director of Government Relations

A "covered position" is a government job the lobbyist held in the 20 years before registering, which the law requires them to name. See the revolving door for former members of Congress across all filings.

Government bodies contacted 4

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 1

Alcohol and Drug Abuse

FenBlock is a patented, non-invasive medical device designed to help patients safely taper off prescribed fentanyl patches by gradually reducing the amount of medication absorbed through the skin.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.